CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Ascendis Pharma A/S (ADR) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Ascendis Pharma A/S (ADR)
Tuborg Boulevard 12
Phone: +45 70222244p:+45 70222244 HELLERUP, 2900  Denmark Ticker: ASNDASND
Business Summary
Ascendis Pharma A/S is a Denmark-based biopharmaceutical company operating within the life sciences and biotechnology sector. The Company scope of activity includes discovery, development, and commercialization of innovative therapies for rare diseases and serious chronic conditions with significant unmet medical needs where a clinically validated parent drug or pathway is suitable to company technologies. Ascendis Pharma A/S focuses on the endocrinology area and has a pipeline of three independent rare disease product candidates, such as Growth Hormone Deficiency (GHD), Hypoparathyroidism and Achondroplasia. The second therapeutic area is oncology, where the company focuses immunotherapy to targeted therapies.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202512/31/2025YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board AlbertCha 53 5/1/2021 11/1/2014
President, Chief Executive Officer, Executive Director, Member of the Executive Board Jan M.Mikkelsen 47 12/1/2007 12/1/2007
Chief Financial Officer, Executive Vice President, Member of the Executive Board Scott T.Smith 52 1/1/2025 8/8/2016
12 additional Officers and Directors records available in full report.

Business Names
Business Name
Ascendis Pharma Belgium BV
Ascendis Pharma Bone Diseases A/S
Ascendis Pharma Endocrinology Division A/S
16 additional Business Names available in full report.

General Information
Number of Employees: 1,189 (As of 12/31/2025)
Outstanding Shares: 61,977,408 (As of 12/31/2025)
Shareholders: 2
Stock Exchange: NASD


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 18, 2026